Compare Amphastar Pharmaceuticals Inc (AMPH) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Marqeta Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.3 (market cap $826.08M), while Marqeta Inc trades at $16.2 (market cap $1.67B). The key difference: Marqeta Inc is far larger — about 2× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | MQ | |
|---|---|---|
Market Cap | $826.08M | $1.67B |
Sector | Health | Technology |
52-Week High | $30.81 | $27.32 |
52-Week Low | $16.87 | $15.04 |
Enterprise Value | $1.22B | $972.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
MQ trades at $15.87, up 2.32% today, with a bearish technical signal and neutral oscillators. Revenue has improved from $507M in 2024 to $625M in 2025, though net income remains negative. The company recently announced a 4:1 reverse stock split effective July 1, 2026, and will report Q2 2026 earnings on August 4, 2026. Analyst consensus is a buy rating with a $19.00 price target, indicating potential upside from current levels.
MQ shows revenue growth and expanding European presence, but profitability is weak with a high P/E of 396.75. Risks include ongoing net losses, competitive fintech pressures, and shareholder litigation. The stock offers speculative growth potential if execution improves, but investors face significant fundamental and sentiment headwinds near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
